Laurus Labs stock: Q2 profit surges as dividend date arrives

Published on 11/06/2026 at 01:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Laurus Labs stock enters its interim-dividend record date after a strong September quarter. Payment is scheduled to begin later this month.

Profit Growth Meets Dividend Timing

Laurus Labs reported sharp year-on-year growth in revenue, operating profit and net income for the September quarter.
The board set November 6 as the record date for an interim dividend, with payment scheduled from November 19.
CDMO demand and small-molecule products were central to the quarter's expansion.

Laurus, INE947Q01028, Illustration mit AI erstellt.

Laurus Labs reported a strong second quarter for fiscal 2027, with revenue rising 33 percent year on year to INR 2,206 crore and net income reaching INR 441 crore, according to Zee Business. The results cover the quarter ended September 30, 2026.

CDMO Growth Drives Earnings

EBITDA increased to INR 762 crore, while the margin widened to 34.5 percent from 26 percent a year earlier. Contract development and manufacturing revenue rose 75 percent to INR 904 crore, led by small-molecule activity and the ramp-up of new assets.

Laurus Labs also operationalised its first commercial-scale peptide manufacturing plant in Visakhapatnam. The facility has solid-phase peptide synthesis capacity of more than 16,000 litres, positioning the company to expand its peptide manufacturing offering as demand develops.

Dividend Record Date Arrives

The board approved an interim dividend of INR 1 per share for fiscal 2027. November 6, 2026 is the record date for determining eligible shareholders, and payment is scheduled to begin on or after November 19.

The company also agreed to acquire a 60 percent stake in Canada's Galenvs Sciences for USD 3.75 million. The transaction is intended to add oligonucleotide and precision magnetic nanoparticle capabilities to Laurus Labs' development and manufacturing platform.

Pharmaceutical Platform Expands

Laurus Labs is headquartered in Hyderabad, India, and operates as a diversified pharmaceutical company focused on medicines, active pharmaceutical ingredients and contract development and manufacturing. Its portfolio includes antiretroviral, antidiabetic, cardiovascular, oncology and gastrointestinal products, as well as oral solid dosage forms and specialised ingredients. The company serves international pharmaceutical markets through manufacturing, research and distribution activities.